title: Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients.
abstract: OBJECTIVE
  To evaluate the quality of life outcomes in antiretroviral-naive patients randomized to zidovudine plus didanosine versus zidovudine plus didanosine plus nevirapine for treatment of advanced HIV disease (the Istituto Superiore di Sanità 047 trial).
  
  
  METHODS
  A 48-week randomized, double-blind trial.
  
  
  METHODS
  Sixty patients were enrolled and evaluated over 24 weeks. Quality of life was assessed using a modified version of the Medical Outcomes Study-HIV Health Survey. For analysis, we calculated two summary scores reflecting the physical (PHS) and the mental (MHS) components of health.
  
  
  RESULTS
  Although the three-drug combination was superior at inducing immunologic and virologic responses, the two-drug regimen was superior for both PHS and MHS, especially at week 8 where differences were both statistically and clinically significant (5.8 and 9.2 points, respectively, P< 0.02 for both). Quality of life changes paralleled trends in body weight and Karnofsky performance status score.
  
  
  CONCLUSIONS
  Although a three-drug antiretroviral therapy regimen was superior in terms of short term virologic/immunologic response, the two-drug regimen was better in terms of quality of life. In general, triple therapy remains the most effective treatment option. However, quality of life assessments can yield results that may be discordant with and complementary to those obtained using conventional endpoints. Comparative trials should collect a comprehensive range of outcome measures, including patient-reported quality of life, in order to provide clinicians and patients with additional information that may influence treatment decisions.
authors: Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy. r.bucciardini@iss.it
authors: R
authors: R
authors: Bucciardini
authors: A W
authors: AW
authors: Wu
authors: M
authors: M
authors: Floridia
authors: V
authors: V
authors: Fragola
authors: D
authors: D
authors: Ricciardulli
authors: C
authors: C
authors: Tomino
authors: L E
authors: LE
authors: Weimer
authors: M F
authors: MF
authors: Pirillo
authors: M
authors: M
authors: Mirra
authors: M
authors: M
authors: Marzi
authors: G
authors: G
authors: Giannini
authors: C M
authors: CM
authors: Galluzzo
authors: M
authors: M
authors: Andreotti
authors: M
authors: M
authors: Massella
authors: S
authors: S
authors: Vella
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D016049:Didanosine / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000627:therapeutic use; D011788:Quality of Life; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D019829:Nevirapine; D016049:Didanosine